Wednesday, 22 May 2019

You are here

Mortality and Hospitalization with Pulmonary Hypertension in Systemic Sclerosis

PHAROS is a prospective cohort studying the natural history of pulmonary hypertension (PH) in systemic sclerosis (SSc). They have shown that risk factors for poor outcomes in this cohort included male sex, DLCO < 50%, exercise oxygen desaturation, and pericardial effusions. 

They identified 236 at-risk for PH patients from this population (ECHO systolic pulmonary arterial pressure > 40 mmHg, or DLCO < 55% predicted or ratio of % forced vital capacity/%DLCO > 1.6, measured by pulmonary function testing).

This cohort was followed for 4 years (range 0.4–8.5 yrs), and 35/236 (15%) developed PH after entry (PH group).

In the at-risk group, higher mortality was strongly associated with male sex, low %DLCO, exercise oxygen desaturation, anemia, abnormal dyspnea scores, and baseline pericardial effusion.

PH patients with DLCO < 50% had the highest risk of cardiopulmonary hospitalizations.  Other risks for cardiopulmonary hospitalization were \increased dyspnea and pericardial effusions.

Identification of this at risk group should lead to closer monitoring, ECHO and possibly right heart catheterization to receive appropriate intervention.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Risk Score Predicts Thrombosis Recurrence in APS

A combination risk score helped predict recurrent thrombosis -- particularly arterial -- among patients with antiphospholipid syndrome (APS), an international study found.

Racial Disparities in Mortality Associated with Systemic Lupus Erythematosus

A Morbidity and Mortality Weekly Report on a registry of systemic lupus erythematosus (SLE) patients from two Georgia counties (Fulton and Dekalb) shows SLE mortality was 2-3 times higher compared to the general population, especially amongst blacks; notably deaths occurred sooner after diagnosis and at a mean age approximately 13 years younger.

Calcineurin Inhibitors in Anti-Synthetase Dermatomyositis ILD

A pilot treatment study of patients with anti-aminoacyl-tRNA synthetase antibody–positive polymyositis/dermatomyositis-associated interstitial lung disease (anti-ARS-PM/DM-ILD) shows therapy with glucocorticoids and calcineurin inhibitors (CNI) to be highly effective. 

Biomarkers Predict Thrombosis in Lupus

A composite risk score that included three biomarkers predicted thrombotic events among patients with systemic lupus erythematosus (SLE), a cross-sectional study found.

Monocyte Patrolling Contributes to Lupus Glomerulonephritis

Systemic lupus erythematosus (SLE) is an autoimmune disease with a propensity to develop glomerulonephritis (47-70%) or end-stage kidney disease despite therapy.

Hallmarks of the disease are the appearance of immune complexes (IC) containing autoreactive Abs and TLR-activating nucleic acids, whose deposition in kidney glomeruli is suspected to promote tissue injury and glomerulonephritis (GN).